Acasti Pharma Inc. Reports Positive Impacts on Cardiometabolic Associated Disorders
September 02 2010 - 12:39PM
This release replaces and supersedes the press release sent earlier
today. Acasti Pharma Inc., a subsidiary of Neptune Technologies
& Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX-V:NTB)
reports significant results on the effects of its anti-dyslipidemic
investigational drug candidate CaPre™ on C-reactive protein (CRP)
levels, a biomarker of CardioVascular Disease risk (CVD) and
associated with diabetes and obesity.
Severe dyslipidemic animals were treated once-daily
with either 0.5g or 2.5g CaPre™ human equivalent dosing per
day for 28 days. After dosing, circulating plasma concentrations of
total CRP were measured using a commercially-available and
validated immunoassay kit. The treated animals benefited from the
treatment resulting in a reduction of CRP levels by 15% and 24%,
respectively.
It is recognized by the American Heart Association that testing
CRP levels in the blood may be an additional way to assess
cardiovascular disease risk. In addition, the prevalence of
high CRP levels is accentuated in overweight and obese individuals
now affecting 60% of the population of 20 years and over according
to the Centers for Disease Control and Prevention (Atlanta, USA).
"The present results clearly suggest a beneficial lowering
effect of CaPre™ on CRP. This observation, combined with our
previous findings that CaPre™ reduces triglycerides and
LDL-cholesterol (bad cholesterol) and elevates HDL-cholesterol
(good cholesterol), indicates that CaPre™ offers a more complete
protection against severe dyslipidemia and associated systemic
inflammatory conditions as cardiometabolic syndrome," said
Dr. Farhad Amiri, Associate-Director, Preclinical Studies,
R&D.
"Accumulating evidence in the literature indicates that
C-reactive protein, may be as important as LDL-cholesterol in
assessing the development of atherosclerosis ("hardening of the
arteries") and heart disease," said Dr. Pierre Lemieux, Chief
Operating Officer of Acasti. "Chronic inflammation is associated
with the most prevalent health problems today such as obesity and
diabetes. It is now recognized that significant reduction of CRP
may constitute an additional tool in the systemic management of
800,000 myocardial infractions and 700,000 strokes that occur in
the United States each year," he added.
About Neptune
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the major
component of cell membranes and are essential for all vital cell
processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular conditions within the
over-the-counter, medical food and prescription drug markets.
About NeuroBioPharm
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither NASDAQ nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or
implied by such forward-looking statements. In addition to
statements which explicitly describe such risks and uncertainties,
readers are urged to consider statements labeled with the terms
"believes," "belief," "expects," "intends," "anticipates,"
"will," or "plans" to be uncertain and forward-looking. The
forward-looking statements contained herein are also subject
generally to other risks and uncertainties that are described from
time to time in the Company's reports filed with the
Securities and Exchange Commission and the Canadian
securities commissions.
CONTACT: Neptune Technologies & Bioressources Inc.
Andre Godin, Vice President, Finance & Administration
450-687-2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Acasti Pharma Inc.
Tina Sampalis, President
450-686-4555 (ext : 403)
t.sampalis@acastipharma.com
www.acastipharma.com
Howard Group
Grant Howard
(888) 221-0915
grant@howardgroupinc.com
www.howardgroupinc.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024